Hirulog thrombin inhibitor data

BGEN (Cambridge, Mass.) presented results of two Phase II trials, totalling 4,088 evaluable patients, showing the agent to be safer than heparin but not much more efficaceous in angioplasty.

The end point of procedural failure, defined as death, myocardial infarct (MI), abrupt closure of the artery, or rapid clinical deterioration of cardiac origin, did not differ significantly between patients given the agent and those treated with heparin (11.4 and 12.3 percent, respectively). ...